CA3080657A1 - Sel cristallin d'un inhibiteur de poly(adp-ribose) polymerase tricyclique - Google Patents

Sel cristallin d'un inhibiteur de poly(adp-ribose) polymerase tricyclique Download PDF

Info

Publication number
CA3080657A1
CA3080657A1 CA3080657A CA3080657A CA3080657A1 CA 3080657 A1 CA3080657 A1 CA 3080657A1 CA 3080657 A CA3080657 A CA 3080657A CA 3080657 A CA3080657 A CA 3080657A CA 3080657 A1 CA3080657 A1 CA 3080657A1
Authority
CA
Canada
Prior art keywords
rucaparib
mesylate
anhydrous crystalline
crystalline
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3080657A
Other languages
English (en)
Inventor
Marijan STEFINOVIC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of CA3080657A1 publication Critical patent/CA3080657A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un sel cristallin de rucaparib mesylate et son procédé de préparation. L'invention concerne en outre, une composition pharmaceutique comprenant le sel cristallin de rucaparib mesylate et au moins un excipient pharmaceutiquement acceptable. La composition pharmaceutique selon la présente invention peut être utilisée en tant que médicament, en particulier pour le traitement du cancer.
CA3080657A 2017-11-03 2018-10-31 Sel cristallin d'un inhibiteur de poly(adp-ribose) polymerase tricyclique Abandoned CA3080657A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17199999.8 2017-11-03
EP17199999 2017-11-03
PCT/EP2018/079815 WO2019086509A1 (fr) 2017-11-03 2018-10-31 Sel cristallin d'un inhibiteur de poly(adp-ribose) polymérase tricyclique

Publications (1)

Publication Number Publication Date
CA3080657A1 true CA3080657A1 (fr) 2019-05-09

Family

ID=60245005

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3080657A Abandoned CA3080657A1 (fr) 2017-11-03 2018-10-31 Sel cristallin d'un inhibiteur de poly(adp-ribose) polymerase tricyclique

Country Status (5)

Country Link
EP (1) EP3704124A1 (fr)
JP (1) JP2021501771A (fr)
CA (1) CA3080657A1 (fr)
MX (1) MX2020004545A (fr)
WO (1) WO2019086509A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021156140A1 (fr) 2020-02-03 2021-08-12 Sandoz Ag Polymorphe de mésylate de rucaparib

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495541B1 (en) 1999-01-11 2002-12-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
JP4756229B2 (ja) * 2000-05-10 2011-08-24 日本農薬株式会社 １，３−ジヨードヒダントイン類の製造方法
CA2520997A1 (fr) * 2003-03-31 2004-10-14 Stacie Sara Canan-Koch Sels d'inhibiteurs tricycliques de poly(adp-ribose) polymerases
ATE551345T1 (de) * 2004-09-22 2012-04-15 Pfizer Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on
EP4166558A1 (fr) * 2010-02-12 2023-04-19 Pfizer Inc. Sels et polymorphes de 8-fluoro-2-{4-[(méthylamino} méthyl] phényl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one

Also Published As

Publication number Publication date
MX2020004545A (es) 2020-08-03
JP2021501771A (ja) 2021-01-21
EP3704124A1 (fr) 2020-09-09
WO2019086509A1 (fr) 2019-05-09

Similar Documents

Publication Publication Date Title
US20240156804A1 (en) C-Met Modulator Pharmaceutical Compositions
KR20230009478A (ko) Lnp023의 결정질 형태
US20240287066A1 (en) Crystalline Form of Sotorasib
EP3808742A1 (fr) Polymorphe de selinexor
US12590095B2 (en) Crystalline forms of an orally available, selective kit and PDGFR kinase inhibitor
EP3887356B1 (fr) Cristaux multicomposants d'un inhibiteur de la hif prolyl hydroxylase disponible par voie orale
CA3087392A1 (fr) Formes cristallines du tosylate de niraparib
CA3080657A1 (fr) Sel cristallin d'un inhibiteur de poly(adp-ribose) polymerase tricyclique
CN104755481A (zh) 作为阿片激动剂的α-6-mPEG6-O-羟基可酮的固体盐形式以及其用途
WO2019166385A1 (fr) Forme cristalline ii de darolutamide
WO2021259732A1 (fr) Composés à composants multiples comprenant du zanubrutinib et un dérivé d'acide benzoïque
WO2022069357A1 (fr) Forme cristalline du selpercatinib
EP3587421A1 (fr) Formes cristallines de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo [1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide
US20240327379A1 (en) Mandelate form of 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one
EP4227305A1 (fr) Forme cristalline de sotorasib
EP4100125A1 (fr) Polymorphe de mésylate de rucaparib

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230502